Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206001 | 0.85 | NOS3 (0.38) | ADORA1ADORA3ADORA2ANOS3NOS2 | |
| SCHEMBL3210413 | 0.84 | ADORA1 (0.36) | ADORA1ADORA3ADORA2AGAAHTT | |
| SCHEMBL1918476 | 0.84 | ADORA1 (0.54) | ADORA1ADORA3ADORA2AGAAHTT | |
| SCHEMBL3206456 | 0.83 | ADORA1 (0.35) | ADORA1ADORA3ADORA2A | |
| SCHEMBL14134995 | 0.83 | CACNA1H (0.36) | ADORA1ADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL3218809 | 0.82 | POLB (0.41) | GAADDAH1SMN1; SMN2L3MBTL1TP53 | |
| SCHEMBL3224434 | 0.81 | JAK2 (0.34) | ADORA1ADORA3ADORA2A | |
| SCHEMBL14134952 | 0.81 | ADORA1 (0.33) | ADORA1ADORA3ADORA2ANOS2 | |
| SCHEMBL3209958 | 0.81 | ADORA1 (0.33) | ADORA1ADORA3ADORA2A | |
| SCHEMBL3199658 | 0.81 | ADORA1 (0.40) | ADORA1ADORA3ADORA2AGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | ADORA1 890/4885ADORA3 440/4885ADORA2A 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.